Biotechnology (310) | Services Agreements (310)

Browse by Company

89bio, Inc. (1 contract)
ACADIA PHARMACEUTICALS INC (5)
Accustem Sciences Inc. (1)
Acorda Therapeutics (3)
Acurx Pharmaceuticals, LLC (1)
Adagio Therapeutics, Inc. (2)
Adaptimmune Therapeutics PLC (3)
ADMA BIOLOGICS, INC. (4)
Aeglea BioTherapeutics, Inc. (1)
AKCEA THERAPEUTICS, INC. (1)
Akebia Therapeutics, Inc. (1)
Allakos Inc. (1)
AMARIN CORP PLC (1)
Amplitude Healthcare Acquisition Corp (1)
Aprea Therapeutics, Inc. (2)
Arcellx, Inc. (1)
ARDELYX, INC. (2)
ARENA PHARMACEUTICALS INC (1)
Arsanis, Inc. (6)
Artiva Biotherapeutics, Inc. (3)
ARYA Sciences Acquisition Corp II (2)
Atara Biotherapeutics, Inc. (4)
Aurinia Pharmaceuticals Inc. (1)
AVROBIO, Inc. (1)
Axovant Sciences Ltd. (2)
BELLICUM PHARMACEUTICALS, INC (1)
BICYCLE THERAPEUTICS Ltd (4)
Big Cypress Acquisition Corp. (1)
BioAtla, Inc. (1)
BioLife4D Corp (2)
Black Diamond Therapeutics, Inc. (2)
Blue Water Vaccines Inc. (4)
bluebird bio, Inc. (5)
Bolt Biotherapeutics, Inc. (1)
Cabaletta Bio, Inc. (4)
CAPSTAR SPECIAL PURPOSE ACQUISITION CORP. (2)
CASTLE BIOSCIENCES INC (2)
Chanticleer Holdings, Inc. (1)
Chardan Healthcare Acquisition 2 Corp. (1)
Checkpoint Therapeutics, Inc. (1)
ChemoCentryx, Inc. (1)
COMPASS Pathways plc (2)
Consonance-HFW Acquisition Corp. (2)
Cullinan Oncology, LLC (2)
CytoDyn Inc. (1)
CYTORI THERAPEUTICS, INC. (2)
Dermavant Sciences Ltd (2)
DYADIC INTERNATIONAL INC (3)
Dynamics Special Purpose Corp. (2)
Editas Medicine, Inc. (1)
Emerald Bioscience, Inc. (2)
Emergent BioSolutions Inc. (4)
Evelo Biosciences, Inc. (2)
EVOLUTIONARY GENOMICS, INC. (1)
EXACT SCIENCES CORP (1)
FIBROGEN INC (1)
Flexion Therapeutics Inc (2)
GALECTIN THERAPEUTICS INC (1)
Galecto Inc. (1)
Galera Therapeutics, Inc. (1)
Gemphire Therapeutics Inc. (1)
GENEREX BIOTECHNOLOGY CORP (1)
GERON CORP (3)
GT Biopharma, Inc. (6)
HCW Biologics Inc. (2)
Health Sciences Acquisitions Corp (6)
HEMISPHERX BIOPHARMA INC (7)
HilleVax, Inc. (1)
HUMANIGEN, INC (1)
Immix Biopharma, Inc. (2)
Immuneering Corp (1)
ImmunoCellular Therapeutics, Ltd. (3)
Immunome Inc. (1)
Inhibrx, Inc. (4)
INSMED Inc (1)
Intec Parent Inc. (1)
INTERCEPT PHARMACEUTICALS, INC. (3)
IO Biotech, Inc. (5)
IONIS PHARMACEUTICALS INC (5)
IRONWOOD PHARMACEUTICALS INC (1)
Isoray, Inc. (1)
iTeos Therapeutics, Inc. (1)
Janux Therapeutics, Inc. (1)
KalVista Pharmaceuticals, Inc. (2)
Kiromic Biopharma, Inc. (1)
Kura Oncology, Inc. (1)
Lantern Pharma Inc. (1)
LifeSci Acquisition Corp. (1)
LIXTE BIOTECHNOLOGY HOLDINGS, INC. (1)
Locust Walk Acquisition Corp. (2)
MACROGENICS INC (1)
Magenta Therapeutics, Inc. (1)
MARIZYME INC (2)
Marker Therapeutics, Inc. (1)
MATEON THERAPEUTICS INC (2)
Medovex Corp. (1)
MiNK Therapeutics, Inc. (2)
Monte Rosa Therapeutics, Inc. (2)
Myovant Sciences Ltd. (6)
NantKwest, Inc. (3)
Natera, Inc. (1)
NEUROTROPE BIOSCIENCE, INC. (4)
Neurotrope, Inc. (1)
NTN BUZZTIME INC (1)
ONCOSEC MEDICAL Inc (1)
Opko Health, Inc. (1)
Orchard Therapeutics plc (2)
Organicell Regenerative Medicine, Inc. (1)
Orgenesis Inc. (1)
PALATIN TECHNOLOGIES INC (1)
PhaseBio Pharmaceuticals Inc (2)
PIERIS PHARMACEUTICALS, INC. (1)
POLARITYTE, INC. (1)
PORTOLA PHARMACEUTICALS INC (1)
PROGENITY, INC. (2)
ProMIS Neurosciences Inc. (4)
Propanc Biopharma, Inc. (1)
PROTEOSTASIS THERAPEUTICS, INC. (1)
PTC THERAPEUTICS, INC. (1)
Qrons Inc. (4)
Rezolute, Inc. (1)
Savara Inc (3)
Sensei Biotherapeutics, Inc. (1)
SERA PROGNOSTICS, INC. (1)
Sesen Bio, Inc. (1)
Shattuck Labs, Inc. (1)
Shuttle Pharmaceuticals Holdings, Inc. (1)
Silverback Therapeutics, Inc. (2)
Social Capital Suvretta Holdings Corp. III (10)
SPHERIX INC (2)
Spinning Eagle Acquisition Corp. (3)
Spring Bank Pharmaceuticals, Inc. (4)
SYNLOGIC, INC. (6)
TG THERAPEUTICS, INC. (2)
Tonix Pharmaceuticals Holding Corp. (1)
TScan Therapeutics, Inc. (2)
Ultragenyx Pharmaceutical Inc. (1)
Unicycive Therapeutics, Inc. (1)
Vaccitech plc (1)
Vaxart, Inc. (5)
VBI Vaccines Inc (1)
Vigil Neuroscience, Inc. (2)
VistaGen Therapeutics, Inc. (1)
VITAL THERAPIES INC (12)
Xenetic Biosciences, Inc. (4)
Xilio Therapeutics, Inc. (2)
ZAFGEN, INC. (2)

Recent Contracts

Amendment to Master Manufacturing Services Agreement, dated (bluebird bio, Inc., Filed With SEC on March 29, 2023)
Master Manufacturing Services Agreement, dated June 3, 2016, by and between the Registrant and Lonza Houston, Inc (bluebird bio, Inc., Filed With SEC on March 29, 2023)
Proposal for Service Agreement, dated March 7, 2023, between Shuttle Pharmaceuticals, Inc. and University of Iowa Pharmaceuticals (Shuttle Pharmaceuticals Holdings, Inc., Filed With SEC on March 9, 2023)
First Amendment to the Manufacturing Services Agreement dated February 27, 2023, between Ardelyx, Inc. and Patheon Pharmaceuticals Inc (ARDELYX, INC., Filed With SEC on March 2, 2023)
Service Agreement dated September 29, 2016 between Immunic AG and Daniel Vitt (VITAL THERAPIES INC, Filed With SEC on February 23, 2023)
Service Agreement dated August 22, 2016 between Immunic AG and Dr. Andreas Muehler (VITAL THERAPIES INC, Filed With SEC on February 23, 2023)
Fourth Addendum, dated January 16, 2023, to Service Agreement between Immunic AG and Dr. Andreas Muehler (VITAL THERAPIES INC, Filed With SEC on January 20, 2023)
Fourth Addendum, dated January 16, 2023, to Service Agreement between Immunic AG and Dr. Daniel Vitt (VITAL THERAPIES INC, Filed With SEC on January 20, 2023)
Fourth Addendum, dated January 16, 2023, to Service Agreement between Immunic AG and Dr. Hella Kohlhof (VITAL THERAPIES INC, Filed With SEC on January 20, 2023)
Shared Services Agreement by and between Accustem Sciences Ltd. and Tiziana Life Sciences plc dated as of January 1, 2021 (Accustem Sciences Inc., Filed With SEC on November 17, 2022)
Service Agreement with Gemma Brown, effective September 15, 2022 (Vaccitech plc, Filed With SEC on November 10, 2022)
Amendment to Master Services Agreement by and between the Company and Alwaysraise, LLC dated as of November 9, 2022 (Immix Biopharma, Inc., Filed With SEC on November 9, 2022)
Amendment 4 to the Amended and Restated Agreement For Services Between ADMA BioManufacturing, LLC and Areth LLC (ADMA BIOLOGICS, INC., Filed With SEC on November 9, 2022)
Amendment No. 3 to Commercial Manufacturing Services Agreement dated as of August 1, 2022 by and between Atara Biotherapeutics, Inc. and Charles River Laboratories, Inc (Atara Biotherapeutics, Inc., Filed With SEC on November 8, 2022)
Services Agreement, dated as of November 4, 2022, by and between Morgenesis LLC and Orgenesis Inc (Orgenesis Inc., Filed With SEC on November 7, 2022)
Attachment #4, Attachment #5 and Attachment #6, each dated May 12, 2017, to the Master Services Agreement, dated December 15, 2016, by and between Acadia Pharmaceuticals GmbH and... (ACADIA PHARMACEUTICALS INC, Filed With SEC on November 3, 2022)
Change Order #1 to Master Services Agreement Attachment #1, dated January 3, 2017, by and between Acadia Pharmaceuticals GmbH and Siegfried AG (ACADIA PHARMACEUTICALS INC, Filed With SEC on November 3, 2022)
Master Services Agreement, dated December 15, 2016, by and between Acadia Pharmaceuticals GmbH and Siegfried AG and its affiliates, and Attachment #1, Attachment #2 and Attachment... (ACADIA PHARMACEUTICALS INC, Filed With SEC on November 3, 2022)
Amendment No. 5 dated January 11, 2022 to the Collaborative Research Agreement by and between the University of British Columbia and Provincial Health Services Authority (on... (ProMIS Neurosciences Inc., Filed With SEC on November 1, 2022)
Amendment No. 4 to Market Access Services Agreement by and between Sunovion Pharmaceuticals Inc. and Myovant Sciences GmbH, dated August 9, 2022 (Myovant Sciences Ltd., Filed With SEC on October 26, 2022)
Amendment No. 3 to Market Access Services Agreement by and between Sunovion Pharmaceuticals Inc. and Myovant Sciences GmbH, dated March 15, 2021 (Myovant Sciences Ltd., Filed With SEC on October 26, 2022)
Amended and Restated Manufacturing & Services Agreement by and between Excella GmbH & Co. KG and Myovant Sciences GmbH, dated April 2, 2021 (Myovant Sciences Ltd., Filed With SEC on October 26, 2022)
Amendment to Amended and Restated Services Agreement, dated October 19, 2022, by and between Dominari Financial Inc. and Kyle Wool (SPHERIX INC, Filed With SEC on October 21, 2022)
Amended and Restated Services Agreement, effective as of October 17, 2022, by and between Dominari Financial Inc. and Kyle Wool (SPHERIX INC, Filed With SEC on October 21, 2022)
Amendment No. 1 to Amended and Restated Placement Agent Agreement, dated October 5, 2022 by and between ProMIS Neurosciences Inc. and Ceros Financial Services, Inc (ProMIS Neurosciences Inc., Filed With SEC on October 17, 2022)
Amended and Restated Placement Agent Agreement, dated September 22, 2022, by and between ProMIS Neurosciences Inc. and Ceros Financial Services, Inc (ProMIS Neurosciences Inc., Filed With SEC on October 17, 2022)
Form of Director Services Agreement (Organicell Regenerative Medicine, Inc., Filed With SEC on September 27, 2022)
Master Services Agreement, dated September 9, 2022, by and between Factor Bioscience Inc. and Brooklyn ImmunoTherapeutics, Inc (NTN BUZZTIME INC, Filed With SEC on September 15, 2022)
Shared Services Agreement, between by and between Dong-A ST Co., Ltd. and the Company, dated September 14, 2022 (Gemphire Therapeutics Inc., Filed With SEC on September 14, 2022)
Strategic Service Agreement effective September 19, 2022 by and between ProMIS Neurosciences Inc. and Eugene Williams (ProMIS Neurosciences Inc., Filed With SEC on September 13, 2022)
Amended and Restated Intercompany Services Agreement, by and between Agenus Inc. and MiNK Therapeutics, Inc., dated August 2, 2022, with effect April 1, 2022 (MiNK Therapeutics, Inc., Filed With SEC on August 15, 2022)
Master Services Agreement dated July 19, 2021, between the Company and Azidus Brasil (ImmunoCellular Therapeutics, Ltd., Filed With SEC on August 10, 2022)
Master Agreement for Clinical Trials Services, dated April 2, 2020, by and between ProKidney (formerly RegenMed (Cayman) Ltd.) and Frenova, LLC (Social Capital Suvretta Holdings Corp. III, Filed With SEC on August 9, 2022)
Master Services Agreement, dated February 15, 2021, by and between George Clinical PTY Limited and ProKidney (formerly RegenMed (Cayman) Ltd.) (Social Capital Suvretta Holdings Corp. III, Filed With SEC on August 9, 2022)
Master Services Agreement, dated April 20, 2020, by and between IQVIA RDS Inc. and ProKidney (formerly RegenMed (Cayman) Ltd.) (Social Capital Suvretta Holdings Corp. III, Filed With SEC on August 9, 2022)
China Clinical Trial Services Agreement, dated April 8, 2022, by and between BioAtla, Inc. and Himalaya Therapeutics Limited Company (BioAtla, Inc., Filed With SEC on August 9, 2022)
Master Services Agreement, dated August 14, 2015, by and between CTI Clinical Trial Services Inc. and RegenMedTX, LLC (Social Capital Suvretta Holdings Corp. III, Filed With SEC on August 9, 2022)
Laboratory Service Agreement, dated August 16, 2016, by and among Covance Central Laboratory Services LP, Covance Central Laboratory Services SA` RL and ProKidney (formerly... (Social Capital Suvretta Holdings Corp. III, Filed With SEC on August 9, 2022)
Laboratory Service Agreement, dated August 1, 2017, by and among Covance Central Laboratory Services LP, Covance Central Laboratory Services SA` RL and ProKidney (formerly... (Social Capital Suvretta Holdings Corp. III, Filed With SEC on August 9, 2022)
Amended and Restated Master Services Agreement, by and between the Registrant and Miltenyi Biotec, Inc., dated November 20, 2021 (AVROBIO, Inc., Filed With SEC on August 9, 2022)